Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 616

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 616
---
 |
| Net loss                                                  |     |                          | (17,137 | ) |     |      | (14,076 | ) |     |        | (3,061 | ) |
| Net income (loss) attributable to noncontrolling interest |     |                          |      (5 | ) |     |      |      23 |   |     |        |    (28 | ) |
| Net loss attributable to Kineta, Inc.                     |     | $                        | (17,132 | ) |     | $    | (14,099 | ) |     | $      | (3,033 | ) |

Revenues Licensing revenues were zero for the year ended December 31, 2024 and $5.0 million for the year ended December 31, 2023. The licensing revenues in 2023 were due to the achievement of a development milestone pursuant to the Merck Neuromuscular License Agreement. Under the Merck Neuromuscular License Agreement, Kineta is eligible to receive up to an additional $255.0 million in development milestones, sales milestones and royalties on net sales. Kineta is not able to estimate when it expects to earn its next $5.0 million development milestone under the Merck Neuromuscular License Agreement. Collaboration revenues were zero for the year ended December 31, 2024 and $442,000 for the year ended December 31, 2023 as a result of research services provided under the Merck Neuromuscular License Agreement pursuant to which Kineta became a successor in interest in connection with the Kineta-Yumanity Merger. Upon completion of the Kineta-Yumanity Merger, Kineta had $442,000 in deferred revenue under the Merck Neuromuscular License Agreement and completed the project services during the year ended December 31, 2023. As of December 31, 2024 and 2023, Kineta had zero in deferred revenue under the Merck Neuromuscular License Agreement. Kineta does not expect to earn any revenue from this license in the forseeable future. 397

Research and Development Expenses The following table summarizes Kineta’s research and development expenses by program and category for the periods presented:

| Direct external program expenses:       |     | Years Ended December 31, 
 2024                     |       |     | 2023           
 (in thousands) |       |     | Change |        |   |
|:----------------------------------------|:----